Lipid nanoparticles have earned their place as the delivery platform of choice for RNA therapeutics. The COVID-19 vaccines proved they could work at global scale, and a growing pipeline of siRNA, mRNA, and gene editing therapies has validated their versatility. But there is a problem the field has been grappling with quietly for years: most LNPs, when administered systemically, end up in the liver. For hepatic indications, that's fine. For everything else, such as T cells, tu

At Reprogram Biosciences, cell reprogramming is at the center of a new way of thinking about therapeutics. Below, Rustam Esanov (CEO) and Eziz Kuliyev (COO) from Reprogram Bio shares—in their own words—how the team is approaching this shift, where they are focusing first, and how partnering with Helix has helped accelerate their work.​ Reprogram’s Mission and Current Focus “To start, could you give a quick overview of Reprogram Biosciences and what your current main project

When Should You Use a Standard LNP Composition versus a Custom Lipid/Polymer Formulation?